A secondary analysis showed that higher dosages of albumin were associated with a lower incidence of vasospasm, DCI, and cerebral infarction at 90 days, in a dose‐dependent fashion.97 Further studies are currently underway to further evaluate the role of albumin in the management of aSAH and cerebral vasospasm. This evidence concerns the gene ALB and cerebral infarction.